Allosteric transcription factor inhibitor discovery platform
exploratoryplatform · high · Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify and develop oral small molecule inhibitors of transcription factors for serious underserved diseases.
Platform identifies novel allosteric sites that emerge through dynamic structural changes in transcription factors.
Altay received a 2023 Astellas Golden Ticket award and is described as developing oral small molecule transcription factor inhibitors.
Allosteric Transcription Factor Inhibitor Discovery Platform
exploratoryplatform · high · Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify and develop oral small molecule inhibitors of transcription factors for serious underserved diseases.
Platform identifies novel allosteric sites that emerge through dynamic structural changes in transcription factors.
Altay received Golden Ticket awards from Bristol Myers Squibb in 2021 and Astellas Therapeutics in 2023.
DX5057 DUX4 inhibitor for FSHD
preclinicaldrug program · high
Develop an oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy and advance it toward clinical trials.
Oral small molecule transcription factor inhibition targeting DUX4.
SOLVE FSHD invested in Altay Therapeutics in 2022 to accelerate drug development and shorten time to clinical trials.
DX5057 DUX4 Inhibitor for FSHD
preclinicaldrug program · high
Develop an oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy.
Oral small molecule transcription factor inhibition targeting DUX4.
SOLVE FSHD invested in Altay Therapeutics in September 2022 to accelerate drug development and shorten time to enter clinical trials.
STAT3 inhibitor program
undiscloseddrug program · high
Develop a STAT3 inhibitor for inflammatory diseases and oncology.
Small molecule transcription factor inhibition, using Altay's approach to identify allosteric sites in transcription factors.
Listed in Altay's pipeline as a STAT3 inhibitor for inflammatory diseases and oncology.
STAT3 Inhibitor Program
preclinicaldrug program · medium
Develop a STAT3 inhibitor for inflammatory diseases and oncology.
Small molecule transcription factor inhibition targeting STAT3.
Listed in Altay's pipeline as a STAT3 inhibitor for inflammatory diseases and cancer/oncology.
Undisclosed oncology program
undiscloseddrug program · medium
Develop an oncology therapeutic program based on Altay's transcription factor inhibitor platform.
Undisclosed therapeutic approach within oral small molecule transcription factor inhibition.
Listed in the supplied pipeline as an undisclosed program in oncology.
Undisclosed Oncology Program
undiscloseddrug program · medium
Develop an oncology therapeutic program; specific target and indication are not disclosed in the supplied material.
Undisclosed; listed alongside Altay's transcription factor inhibitor pipeline.
Listed as an undisclosed oncology program in the supplied pipeline information.
